

Giovanni Luca Ceresoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1724473/publications.pdf>

Version: 2024-02-01

97
papers

5,643
citations

136950

32
h-index

76900

74
g-index

99
all docs

99
docs citations

99
times ranked

5924
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 643-655.	6.3	1,517
2	Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1133-1141.	6.3	367
3	Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor-Positive Non-Small-Cell Lung Cancer Patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 5007-5018.	1.6	367
4	Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. <i>Annals of Oncology</i> , 2004, 15, 1042-1047.	1.2	322
5	Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. <i>Radiotherapy and Oncology</i> , 2003, 67, 275-283.	0.6	253
6	Gefitinib in Pretreated Non-Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC. <i>Journal of Clinical Oncology</i> , 2003, 21, 2658-2663.	1.6	213
7	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1-Positive, Advanced Non-Small-Cell Lung Cancer in the KEYNOTE-010 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1580-1590.	1.6	189
8	Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment. <i>Cancer</i> , 2002, 95, 605-612.	4.1	159
9	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/ gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	1.2	122
10	Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 688-694.	0.8	112
11	Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. <i>Lung Cancer</i> , 2001, 34, 279-287.	2.0	109
12	Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. <i>British Journal of Cancer</i> , 2008, 99, 51-56.	6.4	107
13	Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin. <i>Clinical Cancer Research</i> , 2011, 17, 2581-2590.	7.0	94
14	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. <i>Annals of Oncology</i> , 2006, 17, 1120-1127.	1.2	93
15	Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. <i>Cancer</i> , 2008, 112, 1555-1561.	4.1	89
16	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. <i>Annals of Oncology</i> , 2015, 26, 2107-2113.	1.2	85
17	Second-line treatment for malignant pleural mesothelioma. <i>Cancer Treatment Reviews</i> , 2010, 36, 24-32.	7.7	78
18	Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1146-1155.	1.1	77

#	ARTICLE	IF	CITATIONS
19	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. <i>British Journal of Cancer</i> , 2005, 93, 1334-1340.	6.4	73
20	Primary pulmonary meningioma. <i>Lung Cancer</i> , 2008, 62, 401-407.	2.0	73
21	Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 651-658.	0.8	71
22	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019, 123, 98-105.	2.5	70
23	Assessment of tumor response in malignant pleural mesothelioma. <i>Cancer Treatment Reviews</i> , 2007, 33, 533-541.	7.7	56
24	Target delineation in post-operative radiotherapy of brain gliomas: Interobserver variability and impact of image registration of MR(pre-operative) images on treatment planning CT scans. <i>Radiotherapy and Oncology</i> , 2005, 75, 217-223.	0.6	54
25	Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). <i>British Journal of Cancer</i> , 2004, 90, 82-86.	6.4	52
26	Molecular Alterations in Spontaneous Sputum of Cancer-Free Heavy Smokers: Results from a Large Screening Program. <i>Clinical Cancer Research</i> , 2008, 14, 1913-1919.	7.0	52
27	Multidisciplinary Treatment of Malignant Pleural Mesothelioma. <i>Oncologist</i> , 2007, 12, 850-863.	3.7	49
28	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1438-1447.	10.7	45
29	Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 674-683.	0.8	42
30	Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 667-675.	6.4	42
31	Imaging in pleural mesothelioma: A review of Imaging Research Presented at the 9th International Meeting of the International Mesothelioma Interest Group. <i>Lung Cancer</i> , 2010, 70, 1-6.	2.0	41
32	Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6006-6012.	7.0	40
33	Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. <i>Lung Cancer</i> , 2020, 140, 59-64.	2.0	33
34	Evaluation of radiological and pathological prognostic factors in surgically-treated patients with bronchoalveolar carcinoma. <i>European Journal of Cardio-thoracic Surgery</i> , 2001, 20, 367-371.	1.4	31
35	Anatomic Variations Due to Radical Prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 563-572.	2.0	26
36	Prognostic and predictive role of [¹⁸ F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. <i>Cancer Medicine</i> , 2017, 6, 2287-2296.	2.8	22

#	ARTICLE	IF	CITATIONS
37	Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2004, 44, 231-239.	2.0	21
38	Prostatic Stromal Tumor with Fatal Outcome in a Young Man: Histopathological and Immunohistochemical Case Presentation. <i>Rare Tumors</i> , 2010, 2, rt.2010.e57.	0.6	21
39	MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data. <i>Oncotarget</i> , 2015, 6, 42053-42066.	1.8	20
40	Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2019, 20, 82-87.	2.6	19
41	Role of Computed Tomography and [18F] Fluorodeoxyglucose Positron Emission Tomography Image Fusion in Conformal Radiotherapy of Non-Small Cell Lung Cancer: A Comparison with Standard Techniques with and without Elective Nodal Irradiation. <i>Tumori</i> , 2007, 93, 88-96.	1.1	18
42	CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 105-112.	4.2	18
43	Immune checkpoint inhibitors in malignant pleural mesothelioma. <i>Lancet Oncology</i> , The, 2017, 18, 559-561.	10.7	18
44	Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study. <i>Cancer Management and Research</i> , 2017, Volume 9, 789-800.	1.9	16
45	Clinical staging of malignant pleural mesothelioma: current perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 127-139.	2.7	16
46	Immune checkpoint inhibitors in mesothelioma: a turning point. <i>Lancet</i> , The, 2021, 397, 348-349.	13.7	15
47	Anti-angiogenic therapies for malignant pleural mesothelioma. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 833-844.	4.1	13
48	Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CANcer) trial. <i>Lung Cancer</i> , 2019, 134, 210-217.	2.0	12
49	Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?. <i>Lung Cancer</i> , 2020, 145, 208-210.	2.0	12
50	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory FoRECATT study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1583-1592.	4.2	12
51	Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma. <i>Cancer Treatment Reviews</i> , 2015, 41, 853-858.	7.7	11
52	Mediastinal follicular dendritic cell sarcoma. <i>Haematologica</i> , 2003, 88, ECR04.	3.5	11
53	Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3775-3782.	2.4	10
54	Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, e529-e531.	1.6	9

#	ARTICLE	IF	CITATIONS
55	Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges. Expert Review of Anticancer Therapy, 2016, 16, 673-675.	2.4	9
56	Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study. International Journal of Molecular Sciences, 2022, 23, 5786.	4.1	9
57	Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences. Cytokine and Growth Factor Reviews, 2017, 36, 25-31.	7.2	8
58	Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. Lung Cancer, 2020, 140, 71-79.	2.0	8
59	Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. Clinical Lung Cancer, 2021, 22, 361-370.e3.	2.6	8
60	P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment. Frontiers in Oncology, 2021, 11, 653497.	2.8	8
61	Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. Journal of Clinical Oncology, 2014, 32, 471-471.	1.6	8
62	FDG PET/CT metabolic tumour volume in small-cell lung cancer: better staging and prognostic stratification for an improved therapeutic strategy. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 921-924.	6.4	7
63	ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.. Journal of Clinical Oncology, 2017, 35, TPS8582-TPS8582.	1.6	7
64	Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01â€“2014). BMC Cancer, 2017, 17, 493.	2.6	6
65	Abstract CT201: Final results of Phase II STELLAR trial: TTFIELDS with chemotherapy in unresectable malignant pleural mesothelioma. Cancer Research, 2019, 79, CT201-CT201.	0.9	5
66	In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma. Nuclear Medicine Communications, 2019, 40, 1179-1186.	1.1	4
67	Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE. Journal of Bone Oncology, 2021, 26, 100341.	2.4	4
68	Second-line treatment in malignant pleural mesothelioma: translating the evidence into clinical practice. Lung Cancer Management, 2014, 3, 263-271.	1.5	3
69	Radiotherapy to intervention sites in mesothelioma: no more?. Lancet Oncology, The, 2016, 17, 1025-1027.	10.7	3
70	Irradiation Fields and Doses in Glioblastoma Multiforme: Are Current Standards Adequate?. Tumori, 2001, 87, 85-90.	1.1	2
71	EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. Expert Opinion on Medical Diagnostics, 2007, 1, 183-191.	1.6	2
72	Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer. Investigational New Drugs, 2007, 25, 559-564.	2.6	2

#	ARTICLE	IF	CITATIONS
73	1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM). <i>Annals of Oncology</i> , 2020, 31, S1078.	1.2	2
74	A reply to "managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy". <i>Lung Cancer</i> , 2021, 157, 165-166.	2.0	2
75	Trabectedin (T) as second line treatment option for patients with epithelioid malignant pleural mesothelioma (MPM) in progression following pemetrexed/platin-derivates chemotherapy: ATREUS trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8513-8513.	1.6	2
76	Vinflunine (VFL) in patients (pts) with metastatic transitional cell carcinoma of the urothelial tract (mTCCU): Clinical outcome and prognostic factors in a nationwide, real-life setting (MOVIE trial).. <i>Journal of Clinical Oncology</i> , 2016, 34, e16031-e16031.	1.6	2
77	Short Schedule of Cisplatin and Vinorelbine: A Dose-Finding Study in Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2006, 71, 229-236.	1.9	1
78	Is gemcitabine cost effective in cancer treatment?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 239-249.	1.4	1
79	Approved and emerging treatments of malignant pleural mesothelioma in elderly patients. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1179-1188.	2.5	1
80	Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8506-8506.	1.6	1
81	Intermittent maintenance treatment with bevacizumab in patients with metastatic colorectal cancer: A single centre experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, 776-776.	1.6	1
82	Abstract CT202: Safety of Tumor Treating Fields delivery to the torso: Pooled analysis from TTFIELDS clinical trials. , 2019, , .		1
83	RAMES study: is there really a role for VEGF inhibition in mesothelioma? " Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e533.	10.7	1
84	Optimizing Anti-EGFR Strategies in Cancer Treatment. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 267-275.	0.3	0
85	In Response to Dr. Russi and Colleagues. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1279-1280.	0.8	0
86	Adjuvant radiotherapy for malignant pleural mesothelioma: Challenges and pitfalls. <i>Radiotherapy and Oncology</i> , 2012, 105, 271.	0.6	0
87	Updated report of an observational clinical registry (REGCLIN-MM) on malignant pleural mesothelioma (MPM). <i>Annals of Oncology</i> , 2017, 28, vi59.	1.2	0
88	Multicentre, double-blind, randomised phase II study evaluating gemcitabine with or without ramucirumab as II line treatment for MPM. <i>Annals of Oncology</i> , 2018, 29, viii644.	1.2	0
89	Malignant pleural mesothelioma (MPM) in elderly patients: A multicenter survey.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7082-7082.	1.6	0
90	Clinicopathological features of patients with malignant mesothelioma in a multicenter, retrospective study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e12651-e12651.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Final results of a phase II study of oral vinorelbine (NVBo) monotherapy in patients (pts) with advanced EGFR-positive non-small-cell lung cancer (NSCLC) after failure of EGFR-TKI in first line (NAVotRIAL 2).. Journal of Clinical Oncology, 2016, 34, e20546-e20546.	1.6	0
92	Clinical outcome of EGFR-mutant NSCLC patients continuing TKIs beyond progression in combination with local ablative radiotherapy.. Journal of Clinical Oncology, 2017, 35, e20662-e20662.	1.6	0
93	Prognostic value of neutrophil-to-lymphocyte ratio in advanced EGFR-mutated non-small cell lung cancer (NSCLC) treated with a tyrosine-kinase inhibitors: A retrospective analysis in a series of western patients.. Journal of Clinical Oncology, 2017, 35, e23045-e23045.	1.6	0
94	Predictive impact of different exon 19 deletions in EGFR-mutant NSCLC treated with first-line TKIs.. Journal of Clinical Oncology, 2017, 35, e20608-e20608.	1.6	0
95	Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2018, 36, 8568-8568.	1.6	0
96	Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.. Journal of Clinical Oncology, 2018, 36, 8566-8566.	1.6	0
97	Role of Chemotherapy in the Management of Malignant Pleural Mesothelioma. , 2019, , 221-233.		0